Maridea Wealth Management LLC Takes $1.47 Million Position in Icon Plc $ICLR

Maridea Wealth Management LLC acquired a new position in Icon Plc (NASDAQ:ICLR) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 7,813 shares of the medical research company’s stock, valued at approximately $1,472,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Private Trust Co. NA increased its position in shares of Icon by 200.0% in the 3rd quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 94 shares during the last quarter. Wilmington Savings Fund Society FSB grew its stake in shares of Icon by 153.4% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 332 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 201 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Icon by 40,800.0% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 409 shares of the medical research company’s stock valued at $59,000 after buying an additional 408 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new position in shares of Icon in the 2nd quarter valued at about $61,000. Finally, Pilgrim Partners Asia Pte Ltd acquired a new stake in shares of Icon during the 3rd quarter valued at approximately $63,000. 95.61% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on ICLR shares. Rothschild & Co Redburn set a $100.00 target price on shares of Icon and gave the stock a “neutral” rating in a research report on Tuesday. Mizuho set a $216.00 price objective on Icon in a research note on Friday, January 9th. TD Cowen reaffirmed a “hold” rating on shares of Icon in a research report on Thursday, February 12th. Leerink Partners reiterated a “market perform” rating and set a $105.00 target price on shares of Icon in a research note on Thursday, February 12th. Finally, UBS Group set a $220.00 price target on shares of Icon in a research note on Friday, October 24th. Four equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $164.33.

Icon Price Performance

Shares of NASDAQ:ICLR opened at $88.62 on Wednesday. The firm’s 50 day moving average is $172.29 and its two-hundred day moving average is $173.74. The firm has a market capitalization of $7.16 billion, a P/E ratio of 11.99, a PEG ratio of 1.96 and a beta of 1.27. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31. Icon Plc has a 52 week low of $66.57 and a 52 week high of $211.00.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.